SREBP2-regulated inhibition of mevalonate pathway is a target for cancer therapy and several preclinical studies have shown that modulating SREBP2 activity reflects to the activity of the mevalonate pathway, as reviewed by Xue and coworkers (Xue et al. 2020). Here, SREBF2 is linked to cancer.